Does earlier diagnosis and treatment of brain tumours matter? Time-to-treatment intervals and tumour size at detection; impact on survival and other patient outcomes

Clicks: 12
ID: 330013
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #123 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The importance of timely diagnosis of brain tumours is well recognised but how this translates to impact on important patient outcomes is not well described. This observational study aimed to quantify the effect of time-to-treatment interval and tumour size at diagnosis on six patient outcomes: tumour-specific survival, overall survival, new or worsened neurological deficit, 30-day mortality, recurrence and inpatient length of stay. Methods A retrospective cohort study including 1196 patients from Southeast Scotland diagnosed with brain tumours between 2010 and 2020. Analysis was stratified by tumour type in three categories: Glioblastoma (GBM) and other grade 4 brain tumours, grade 1-3 tumours and brain metastases. Regression methods (Cox, Logistic & Linear) were used to estimate per day impact of time-to treatment and tumour size impact on outcomes. Results The mean time from first presentation to treatment was 161 days (median: 57 days. Time-to-treatment results showed an association between longer intervals and reduced mortality. The mean tumour size was 4.06cm (SD: 1.75cm). For GBM and grade 4 tumours, each 1cm increase in tumour size increased tumour-specific mortality risk by approximately 11% (HR: 1.11, 95%CI: 1.05-1.16) and increased all-cause mortality by 10% (HR: 1.10, 1.05-1.16). Associations between tumour size and the outcomes of brain tumour mortality, all-cause mortality and inpatient length of stay were consistent across tumour subgroups. Conclusions Larger tumour size was consistently associated with increased hazard ratios for mortality. Applying these estimates together with estimates of mean tumour growth rates available in the literature, if a 6cm Glioblastoma tumour were diagnosed 3 months earlier then we would expect a 17-26% reduction in hazard of brain tumour mortality. Importance of the Study These findings reinforce the potential positive impact of earlier diagnosis for brain tumour patients. Building upon the accumulated evidence that tumour size is a critical factor influencing prognosis, this study is the first to focus on estimating causal associations with patient outcomes. Earlier detection, through influence on tumour size at diagnosis, may offer measurable survival benefits and potential reductions in healthcare resource use. There are limitations of an observational study design, but we believe our large, robust dataset and detailed analysis provide a stronger foundation for advocating further prospective research such as trials or pilots of early diagnostic interventions.
Reference Key
openalex_W7214640937 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ewan Gray, James Cameron, Abigail Lishman, Peter Hall, Piyumanga Karunaratne, Giovanni Tramonti, Mahéva Vallet, Luke Pike, Matthew Baker, Paul Martin Brennan
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag230
URL
https://doi.org/10.1093/noajnl/vdag230
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.